港股恒生指数涨幅扩大至1%，恒生科技指数现涨1.51%。 ...

Group 1 - The Hong Kong IPO market has shown remarkable performance in the first half of the year, with 31 listings and a total financing amount of 884 billion HKD, surpassing the total financing of the previous year, making Hong Kong the global leader in IPO financing [1] - Institutional innovations have activated the financing momentum of the Hong Kong Stock Exchange, with optimized listing rules and improved approval efficiency being key drivers for attracting companies to list [2] - Leading companies in new economy and technology sectors have significantly contributed to Hong Kong's position as the top IPO financing venue globally, with major firms like CATL and Jiangsu Hengrui Medicine leading the way [2][3] Group 2 - The trend of A-share listed companies, especially in new economy and biomedicine sectors, seeking international development through Hong Kong listings is increasing, as the Hong Kong Stock Exchange responds to the demand for high-quality economic development [3] - The liquidity of the Hong Kong market has improved significantly, with a notable reduction in the price gap between H-shares and A-shares, enhancing the attractiveness of IPOs [4] - The continuous release of institutional dividends, the accelerated gathering of new economy industries, and the increasing convenience of cross-border capital flows are expected to strengthen Hong Kong's competitive advantage in attracting global new economy enterprises [4]

如何展望后续港股走势？20250624 摘要 港股市场受益于前期海外流动性宽松，中小标的和主题性投资活跃，但 市场有能力容纳未来预计上市的 100-200 家 AH 股及美股回归公司，政 策和流动性投放对港股形成托底支持。 港府及证监会对资本市场重视程度提升，政策支持力度增强，为港股提 供稳定基础，使其在外部扰动下仍保持强势，如面对贸易战时亦能反弹 回升。 中长期看好互联网、智能驾驶、新消费等产业方向，如泡泡玛特、老铺 黄金等企业展现全球化潜力，AI 技术推动小米等公司估值提升，创新药 领域亦具成长空间。 推荐腾讯、阿里巴巴等互联网巨头，以及阿尔法逻辑强劲的小米。新消 费领域关注泡泡玛特、老铺黄金等品牌，这些企业通过技术突破和全球 化战略实现增长。 市场对小米新车发布抱有高度期待，预计大单销量可达 25 万辆，月销 量 4 万辆，有望推动股价上涨。长期看好小米在汽车、IoT、手机及机器 人等领域的多元发展。 Q&A 今年以来港股市场表现如何？ 今年以来，港股市场表现非常亮眼。从全球市场来看，港股的收益排名前列。 今年整体的港股市场新股和 IPO 项目较多，加上南下资金不断买入和交易港股， 使得成交量和活跃度都 ...

Group 1 - The Hong Kong IPO market is accelerating, with 17 companies having passed the hearing as of June 24, 2025, and 35 new stocks listed since the beginning of the year [1][3] - Five companies, including Cao Cao Chuxing and Xiangjiang Electric, are set to go public this week [1][3] - The IPO market is experiencing a continuous trend of profitability for investors, with only three out of seven newly listed stocks in June showing a decline [9][12] Group 2 - Cao Cao Chuxing plans to issue 44.18 million shares globally, with a share price of HKD 41.94, aiming to raise approximately HKD 1.853 billion [4] - Xiangjiang Electric intends to issue 68.22 million shares at a price range of HKD 2.86 to HKD 3.35, expecting to raise around HKD 172 million for expansion and upgrades [5] - The IPOs of both companies have attracted cornerstone investors, indicating strong market interest [4][5] Group 3 - The overall IPO market in Hong Kong has seen a low failure rate, with only 10 out of 35 new stocks listed this year experiencing a decline, resulting in a failure rate of 28.57% [9][11] - Notable performers include Yingjie Ankang-B, which saw a first-day increase of 78.71%, and Ying En Biotechnology-B, which surged by 116.70% [10][11] - The Hong Kong Stock Exchange has become the largest fundraising platform globally due to the ongoing IPO boom [12] Group 4 - The enthusiasm for listing in Hong Kong is driven by factors such as the launch of the "Special Line for Science and Technology Enterprises" and the return of Chinese concept stocks [12] - Future IPOs are expected to include more large enterprises and industry leaders, particularly in new consumption and hard technology sectors [12] - The Hong Kong Stock Exchange aims to provide a robust financing platform to support the development of the real economy [12]

正在冲击港股的安井食品（下称"安井"），遭到了投资者连环拷问。 近日，安井食品（603345.SH）召开2024年度暨2025年第一季度业绩说明会，公司业绩、港股上市进展 与海外业务布局等成为关注焦点。 孙婉秋 摄 海外收入仅占1% 董事长刘鸣鸣在业绩会上介绍，公司于今年1月向香港联交所递交A1申请，6月5日举行上市聆讯。目前 各项工作正有序推进。 尽管赴港目的之一是为了加快国际化战略及海外业务布局，但安井当前的海外业绩却十分尴尬。 今年一季度，公司实现营收36亿元，其中境外收入仅3980.31万元，占比仅1%，且同比还下降3.1%。有 投资者质疑这与公司积极布局海外市场相悖。 经理张清苗则将海外业绩下滑归咎于国际关税贸易摩擦，并表示未来将重点拓展东南亚主要国家及地 区，通过在当地寻求战略合作、股权投资或并购等方式设厂，逐步扩大海外业务布局。 然而，目前安井在东南亚尚无实体布局，根基近乎空白。 招股书显示，公司近三年海外收入的占比始终徘徊在1%左右，主要依赖欧美市场，唯一的海外生产基 地还位于英国。 中小股东广投反对票 事实上，中小投资者对安井赴港上市的态度较为消极。 2024年12月的股东大会上，对安井发行 ...

港交所披露易显示，截至6月24日，年内已有17家公司通过港交所聆讯，等待正式登陆港股市场。 | 港股IPO正在提速。2025年以来，港股市场已上市35只新股。而在本周，除开已在周一上市的三花智控等3只个股外，还有曹操出行等5只个股即将上市。 | | --- | | 2508.HK | SAINT BELLA | 2025-06-26 | 主板 | | --- | --- | --- | --- | | 6168.HK | 周六福 | 2025-06-26 | 主板 | | 6883.HK | 颖通控股 | 2025-06-26 | 主板 | | 2619.HK | 香江电器 | 2025-06-25 | 主板 | | 2643.HK | 曹操出行 | 2025-06-25 | 主板 | | 2609.HK | 佰泽医疗 | 2025-06-23 | 主板 | | 2617.HK | 药捷安康-B | 2025-06-23 | 主板 | | 2050.HK | 三花智控 | 2025-06-23 | 主板 | IPO依旧紧锣密鼓 港交所披露易显示，今年已有17家公司通过聆讯，其中曹操出行、香江电器、颖通控股、周 ...

从投资区域来看，中国香港市场投资余额占境外投资余额的51%，是股票、债券境外投资的首选市场。 在低利率环境与资产荒压力持续加剧的背景下，保险资金正加速向港股市场倾斜。6月24日，北京商报记者从业内获悉，中国保险资产管理业协会（以下简 称"保险资管业协会"）近日下发的2024年保险资金境外投资及港股通投资情况调研结果（以下简称"调研结果"）显示，中国香港市场投资余额占境外投资余 额的51%，是股票、债券境外投资的首选市场；2025年，有63%的机构计划加大港股投资规模，主要通过港股通方式增加港股投资。 据了解，保险资管业协会面向具备以外汇形式开展境外投资资格的52家保险机构进行调研，结果显示有38家机构2024年开展了境外投资业务。 在业内人士看来，当前，如何实现保险资金运用的安全性、收益性与流动性平衡，成为行业核心命题。保险资金的投资动向不仅折射出对港股估值优势的认 可，更揭示了长期资金在当前阶段的重要配置逻辑。在此背景下，港股市场凭借高股息特征等，逐渐成为保险资金战略配置的重要方向。 港股成险资"心头好" 在保险资金全球化配置版图中，香港市场的战略地位愈发凸显。 对于港股投资占比高的原因，中央财经大学副教授 ...

Core Points - The China Securities Index Hong Kong Stock Connect Technology Index (CSI Hong Kong Technology, 931573) opened lower but closed higher, increasing by 2.46% to 3184.52 points with a trading volume of 68.697 billion yuan [1] - Over the past month, the CSI Hong Kong Technology Index has decreased by 1.56%, and over the past three months, it has declined by 3.92%, while year-to-date it has risen by 29.38% [1] - The index selects 50 large-cap technology leading companies with high R&D investment and good revenue growth from the Hong Kong Stock Connect, reflecting the overall performance of these companies [1] Index Adjustment and Management - The sample of the CSI Hong Kong Technology Index is adjusted every six months, with adjustments implemented on the next trading day after the second Friday of June and December each year [2] - Weight factors are generally fixed until the next scheduled adjustment, with special circumstances allowing for temporary adjustments [2] - New securities that rank in the top ten by market capitalization will enter the index on the eleventh trading day after being included in the Hong Kong Stock Connect [2] Fund Tracking - Public funds tracking the CSI Hong Kong Technology Index include various funds such as Invesco Great Wall CSI Hong Kong Technology Connect C, Invesco Great Wall CSI Hong Kong Technology Connect A, and several ETFs [2]

Core Viewpoint - Meituan's stock price is currently at HKD 132, showing a rebound of 2.64%, but is struggling near the lower boundary of the Bollinger Bands, with significant resistance at the 10-day and 30-day moving averages [1][3] Technical Analysis - The first support level at HKD 122.5 is crucial; if breached, the stock may drop to the strong support zone at HKD 113.3 [3] - The upper resistance level is at HKD 136.6, and a breakthrough could lead to a challenge of HKD 142.7 [3] - The RSI indicator shows an oversold state at 38, while the VR ratio indicates a buy signal, suggesting a potential technical rebound with a 56% probability [3] - The MACD maintains a sell signal, but momentum oscillators show signs of divergence, indicating possible buying opportunities [1][3] Derivative Products Performance - Citigroup's put option (16254) achieved an 18% increase within two trading days following a 3.53% drop in Meituan's stock price [3][5] - Other put options, such as Morgan Stanley's (64017) and UBS's (63423), recorded gains of 18% and 19%, respectively, with UBS's product being the best-performing short tool of the day [3][5] - HSBC's call option (26318) has a strike price of HKD 150.1 with a leverage of 7.6 times, offering a cost-effective choice for bullish investors [6] - UBS's call option (26512) has a lower leverage of 7.3 times but provides a stable investment option due to its relatively low implied volatility [6] Market Sentiment - The current market sentiment indicates a potential test of the support at HKD 122.5 or a direct challenge to the resistance at HKD 136.6 [12] - The analysis suggests that the breakout of either key price level could significantly alter trading strategies [12]

从中证港股通医疗主题指数持仓的市场板块来看，香港证券交易所占比100.00%。 从中证港股通医疗主题指数持仓样本的行业来看，医疗商业与服务占比35.09%、制药与生物科技服务 占比31.59%、医疗器械占比12.87%、化学药占比12.53%、生物药品占比7.91%。 资料显示，指数样本每半年调整一次，样本调整实施时间分别为每年6月和12月的第二个星期五的下一 交易日。权重因子随样本定期调整而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期 调整日前，权重因子一般固定不变。特殊情况下将对指数进行临时调整。当样本退市时，将其从指数样 本中剔除。样本公司发生收购、合并、分拆等情形的处理，参照计算与维护细则处理。当港股通证券范 围发生变动导致样本不再满足互联互通资格时，指数将相应调整。 金融界6月24日消息，上证指数低开高走，中证港股通医疗主题指数 (港股通医疗主题，932069)上涨 3.01%，报896.72点，成交额131.84亿元。 数据统计显示，中证港股通医疗主题指数近一个月上涨7.54%，近三个月上涨6.79%，年至今上涨 30.22%。 据了解，中证港股通医疗主题指数从港股通证券范围内选取5 ...